Oncolytic Reovirus Immune Priming: A Phase 1b Study of Reolysin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Kevin R. Kelly(Keck Hospital of USC), Steffan T. Nawrocki(University of Arizona), Donna Fernando(University of Southern California), Timothy J. Triche(RF Laboratories (United States)), Kaijin Wu(University of Southern California), Imran Siddiqi(University of Southern California), Denice Tsao‐Wei(Children's Hospital of Los Angeles), Jennifer S. Carew(University of Arizona), Susan Groshen(USC Norris Comprehensive Cancer Center), Grace C. Chang(University of Southern California), Matt Coffey(Oncolytics Biotech (Canada)), Ann Mohrbacher(University of Southern California), Amy S. Lee(University of Southern California), George M. Gill(Oncolytics Biotech (Canada))
Cited by 9
Related Papers
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
|Journal of Clinical Oncology|1999|670
Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential
|Nature reviews. Cancer|2014|633
The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation
|PLoS Genetics|2014|459